Strumento inattivo

Azioni Cubist Pharmaceuticals Inc

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	13/01/15
Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen	21/12/14
Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées	20/12/14
Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	20/12/14
Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	10/12/14

Dirigenti	Titolo	Età	Da
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	01/01/97

Amministratori	Titolo	Età	Da
Martin Hermanus Soeters BRD	Director/Board Member	70	01/09/06
Kenneth J. Martin BRD	Director/Board Member	70	25/09/13

Settore

	Variaz. 1 gen.	Capi.
CSL LIMITED	-3,15%	89,69 Mrd
SAMSUNG BIOLOGICS CO.,LTD.	+3,95%	41,34 Mrd
BIOGEN INC.	-10,51%	33,72 Mrd
UCB	+59,76%	26,11 Mrd
BIOMARIN PHARMACEUTICAL INC.	-20,09%	14,63 Mrd
INCYTE CORPORATION	-8,92%	12,84 Mrd
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11,46%	11,66 Mrd
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43,05%	11,52 Mrd
SWEDISH ORPHAN BIOVITRUM AB	+5,69%	8,92 Mrd